---
title: Ascendia Patented IP Technologies Featured in Annual Report
description: Ascendia Pharma CEO explains how these advanced approaches allow Ascendia to meet timelines and solve challenges with compounds in the article. Read more here.
image: https://ascendiacdmo.com/hubfs/Imported_Blog_Media/emulsol-3-Dec-01-2024-07-09-16-0501-AM.jpg
---

[![Ascendia Pharmaceutical Solutions](https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm2.svg) ![Ascendia Pharmaceutical Solutions](https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm-w2.svg) ](https://ascendiacdmo.com)

[(732) 640-0058](tel:7326400058)

Search the website

[![Ascendia Pharmaceutical Solutions](https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm2.svg) ![Ascendia Pharmaceutical Solutions](https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm-w2.svg) ](https://ascendiacdmo.com)

Search the website

[(732) 640-0058](tel:7326400058)

Search the website

 May 13, 2020

# Ascendia Patented IP Technologies Featured in Bioavailability & Solubility Report

![emulsol](https://ascendiacdmo.com/hs-fs/hubfs/Imported_Blog_Media/emulsol-3-Dec-01-2024-07-09-16-0501-AM.jpg?width=168&height=165&name=emulsol-3-Dec-01-2024-07-09-16-0501-AM.jpg)Ascendia Pharmaceuticals’ suite of three patented IP technologies – AmorSol, EmulSol, and NanoSol – is included in an annual special report on the state of bioavailability and solubility. The report was published in [Drug Development & Delivery](https://drug-dev.com/special-feature-improving-bioavailability-solubility-chemical-physical-modification-vs-formulation-development/), the leading trade media property.

Jim Huang, PhD, CEO, of Ascendia Pharmaceuticals, explains how these advanced approaches allow Ascendia meet stringent timelines and solve difficult challenges with compounds in the article. The company’s approach to utilize lipid nanoparticles (LNP) in its technologies to improve biosolubility and achieve more effective sustained-release properties is also outlined.

![ASC-2024-logo-vert-sm-w2](https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm-w2.svg)

661 US Highway One

North Brunswick, NJ 08902

(732) 640-0058

_______________

[Contact](https://ascendiacdmo.com/contact)  
[Newsroom](https://ascendiacdmo.com/newsroom)  
[Careers](https://ascendiacdmo.com/careers)  
[Privacy Policy](https://ascendiacdmo.com/privacy-policy)

- [LinkedIn ](https://www.linkedin.com/company/ascendia-pharmaceuticals-llc/)

 © 2026 Ascendia Pharmaceutical Solutions. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Patrick Brightman",
    "url" : "https://ascendiacdmo.com/newsroom/author/patrick-brightman"
  },
  "dateModified" : "2024-12-01T07:12:12.917Z",
  "datePublished" : "2020-05-13T04:00:00.000Z",
  "headline" : "Ascendia Patented IP Technologies Featured in Annual Report",
  "image" : [ "https://ascendiacdmo.com/hubfs/Imported_Blog_Media/emulsol-3-Dec-01-2024-07-09-16-0501-AM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://ascendiacdmo.com/newsroom/2020/05/13/ascendia-patented-ip-technologies-featured-in-bioavailability-solubility-report",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://ascendiacdmo.com/hubfs/ASC-2024-logo-vert-sm.svg"
    },
    "name" : "Ascendia Pharmaceutical Solutions"
  }
}
```